The continuous growth of mammography is driven by global acceptance of the demonstrated ability of screening mammography to reduce mortality from breast cancer. An increasing number of benign and malignant tumors are being diagnosed as a result of the growth in mammography, improvements in technology, especially digital mammography, as well as by an increase in patient surveillance. Breast imaging technology for cancer screening continues to improve, with the integration of ultrasound with digital mammography showing promise that an even larger number of small abnormalities will be detected in screening programs. The results of minimally invasive ablative techniques as tested in pilot clinical studies for breast tumor ablation are reviewed. A new x-ray based thermal monitoring method is described. An improved ability to intraoperatively monitor thermal ablative methods may enable more accurate minimally invasive treatment of an ever increasing number of both benign and malignant breast tumors.
screen", single payer Canadian system as well as the less formal, multiple payer US system have achieved compliance rates for mammography screening ranging from 60-80% (5, 6) . Compliance rates with screening guidelines will continue to increase paced by efforts from agencies such as the American Cancer Society which has adopted a goal to achieve 90% compliance with screening guidelines by the year 2008. In addition to established screening programs in Australia and New Zealand, Japan has been considering adopting a population based screening program for several years as its breast cancer incidence is increasing rapidly (7) . In spite of a historical incidence rate of only about 30% of that of the Western world (8), 3.1 cancers per 1000 were detected in a recent screening study in Japan (9), a detection rate that is not much lower than that of an established screening program in Europe (10).
It is estimated that over 100 million women are currently receiving screening mammograms on a worldwide basismostly in Europe and North America -and this number is growing steadily. There are several factors that will cause an increase in the number of mammograms that are performed each year. The major contributors to the increase include:
• Expansion of the age group for screening programs to include women from 40 to 50 years and from 65 to 75 years. • An increase in compliance to screening guidelines. • An increasing number of women aged 40 years and above, driven by the baby boomer demographic bulge in the population as well as by a decline in mortality from competing causes. • An increase in the number of women receiving mammograms outside formal screening programs.
For the United States, the overall impact has been a steady growth in the number of women undergoing mammography. Figure 1 is a graph showing that by 2010 there will be 65 million screening mammograms in the US.
The projected more than 50% increase in the number of mammograms over the year 2000 is driven by a population increase of an additional 10 million women over age 40, a steady increase in screening compliance, and reflects the ultimate achievement of the American Cancer Society's goal of 90% compliance with screening guidelines.
Given the large number of women undergoing regular mammography, significant efforts are underway to improve mammography or to develop an alternate test that is less expensive, and more accurate (11). The sensitivity of screening mammography has recently been measured at a respectable 70-86% (12, 13). Its biggest shortcoming however results from a high false positive rate -especially in younger women with dense breast tissue (14) . Several imaging modalities are currently under study in an attempt to improve on the performance of mammography. Most of these modalities have proven to be effective in breast imaging for diagnostic problem solving (MRI, Ultrasound, SPECT, and PET) but fall short as a technique that could replace screening mammography either due to cost, (MRI, SPECT, and PET) or an inability to cover the entire breast or reliably image microcalcifications (Ultrasound).
The availability of full field digital mammography (FFDM) systems has offered many benefits over analogue (film) mammography but studies to date fail to demonstrate superior sensitivity compared to film mammography (15). However, FFDM systems do provide an opportunity to enable improved performance in screening through the integration of ultrasound with FFDM. By combinatively adding ultrasound to FFDM systems, the strength of mammography (microcalification detection, asymmetries) can be combined with the strength of ultrasound (cystic vs. solid, mass evaluation in 3-D) to produce a superior screening exam. Several studies have been performed to assess the value of ultrasound exams following negative screening mammography in women with dense breasts (16, 17). Kolb et al. (18) performed ultrasound on women with Birads 2-4 overall breast density (i.e., scattered fibroglandular densities, heterogeneously dense, and extremely dense breasts) following negative conventional mammography. Figure 2 summarizes Kolb's findings for the performance of each modality separately and then combinatively. Note that by using both ultrasound and mammography the overall sensitivity increased in the study to 97%. The sensitivity for extremely dense breasts (Birads 4) increased to 95% compared to 48% for mammography alone. Other investigators have reported similar results. Buchberger et al. (19) examined 6,113 women with ultrasound who had negative mammography and Birads 2-4 overall breast density and found an additional 23 cancers, or 3.1 cancers per 1000.
Naturally the cost of performing sequential ultrasound exams could be substantial if applied to the roughly 80% of women estimated to have Birads 2-4 breast density. In addition, interpreting the two exams without a correlated frame of reference would be time consuming and challenging for breast imaging specialists with the possibility of a geographic lesion miss.
Combining ultrasound imaging with FFDM for a screening exam could offer significant benefits over independent, sequential exams. Imaging the breast by ultrasound while in compression would allow the digital x-ray image to be registered with the 3D data of the ultrasound exam. While several different methods for displaying the x-ray and ultrasound images are possible it is likely that a mammographic abnormality will first prompt a reviewer to display only the ultrasound correlate for the same location rather than reviewing the entire ultrasound data set. For example, a mammographic density would be further clarified by the cross sectional ultrasound image of that density, allowing a cyst to be easily visualized without calling the patient back for an additional ultrasound exam.
Several FFDM manufacturers are involved in researching various methods of combining the acquisition of FFDM and US images. GE Medical has developed a working prototype and has been testing the system in a clinical setting. The GE prototype, shown in Figure 3 , acquires the ultrasound image by coupling an ultrasound probe on the top of the mammographic compression plate and scanning the entire breast with a motorized "lawn mower" pattern (20). One could imagine an extended probe that would allow an acquisition of the entire breast in one scanning motion.
Fischer Imaging has been developing a combination screening system based on its SenoScan slot scanning FFDM system. In this implementation, shown in Figures 4a and 4b , the ultrasound image and x-ray image are acquired simultaneously as the assembly is scanned underneath the breast. While the practical implementation of the concept presents engineering challenges, it is expected that a production system could be provided to the market.
The availability of a screening ultrasound/mammography system should improve the sensitivity and specificity of mammography. Adding computer aided detection software, running independently and combinatively on both the x-ray and ultrasound image, would promise to improve overall system performance (21-23).
While the overall performance of integrated FFDM/US is expected to be better than mammography alone, the improvement will likely come at a cost of uncertainty regarding small densities or opacities detected by ultrasound that are otherwise not visualized by x-ray. As a result, the positive predictive value (PPV) of biopsy has suffered when screening ultrasound has been performed following mammography in dense breasts (16 above, 24) While screening mammography results in a PPV for cancer of about 20-30% (25) early studies with screening ultrasound would suggest a PPV of only about 10%. This low PPV may be improved after additional experience resulting from the classic "learning curve", but the early studies have been carried out by experts in breast ultrasound and the ultrasound exams were no different than standard studies -suggesting that the task of characterizing small objects discovered during the exam is difficult. Most likely a PPV and positive biopsy rate of 10% would prevent the technique from reaching widespread implementation due to the high costs of tissue biopsy.
Increasing awareness of breast cancer has created an increase in the number of women seeking medical care for breast abnormalities. Since failure to diagnose breast cancer represents the largest number of malpractice cases in medicine (26), physicians are increasing the use of ultrasound and ultrasound guided needle biopsy for the evaluation of palpable lesions. In the US biopsies of palpable lesions are estimated at about 500,000 procedures/year (27). In addition, about 1.3 million biopsies of non palpable abnormalities detected by mammography are performed with surgical excision, or with needle biopsy under ultrasound or stereotactic guidance. Benign palpable and non palpable lesions are very frequently surgically removed, with procedure estimates ranging from 350,000 to 400,000 surgical excisions/year, mostly for fibroadenomas. In addition to benign masses there are another 250,000 breast cancer surgeries per year including about 50,000 excisions for noninvasive cancer.
(DCIS) Given the high cost of surgical intervention, minimally invasive methods are under study to provide a less expensive and less traumatic means of removing benign breast abnormalities and small cancers.
Minimally Invasive Therapy
Minimally invasive techniques under study include percutaneous removal of the lesion, cryoablation, and thermal ablation. All these techniques are designed to treat lesions outside the operating theater and require image guidance as an integral part of the procedure. Each method provides unique benefits as well as unique challenges.
Cryoablation has been studied for decades and has been approved by the FDA to treat fibroadenomas of the breast (28). A recent study on the office based cryoablation treatment of 70 fibroadenomas in 57 patients reported that 75% of the palpable fibroadenomas became non palpable after 12 months of follow up and that 91% of the patients were pleased with the procedure (29). Studies to treat small cancers are underway but some early studies would suggest difficulties in achieving complete cell death with cryoablation resulting in uncertain margin analysis. A recently published study showed complete necrosis in only 5 out of the 16 cancers treated with cryoablation (30).
Percutaneous techniques for benign lesion removal have been reported using biopsy instruments with some success over a 6 month follow up period (31, 32). For large fibroadenomas, complete removal can be time consuming and bleeding can interfere with ultrasound visualization and thus complete removal. One study noted that "After removal of all US evidence of breast masses with a VAB device, there was a sub-stantial probability that residual lesion that was not visualized during the procedure would later be found at surgery or follow-up imaging." (33). The cost savings compared to surgical excision were substantial and documented at 82% less than surgery while requiring 71% less time to perform the procedure (32 above). While percutaneous approaches to the removal of small cancers are being studied, concerns over removing the entire lesion with adequate margins, removing the lesion in small pieces, and concerns over tumor cell shedding have given pause to most surgical oncologists.
A benefit of a minimally invasive cancer treatment employing thermal therapy results from the coagulation necrosis of the tumor as an alternative to the vascular disruption involved with surgical excision. Some recent evidence has been presented indicating that surgical injury may promote cellular growth factors that could cause tumor cells to proliferate in the event not all cancer cells are removed (34). In addition, it is well-known that such minimal invasive methods avoid the stress to the immune system caused by excisional surgeries. Thermal ablation techniques include radiofrequency (RFA), microwave, High Intensity Focused Ultrasound (HIFU), and Laser Interstitial Thermal Therapy (LITT). All of these techniques rely on the principle of heat killing cells. It has been well established that cells subjected to temperatures of 50º C will die in about one minute while temperatures of 56º C will kill cells in about one second (35). Thermal ablative techniques depend on subjecting all cells within the defined tumor to lethal temperatures during the ablation. Another interesting field of study relating to thermal therapies is the emerging data supporting an antigenic effect created by cancer cells exposed to lethal temperatures. Several research groups have shown that heat shock proteins (HSPs) created as a result of thermal injury to cells have resulted in an immunogenic effect in animal models (36).
Recently published research shows some promise that RFA and microwave thermal therapy used in the treatment of Hepatocellular carcinoma may be benefiting from the creation of heat shock proteins (37, 38) . In an 8 year follow up study of 603 patients with liver metastases treated by LITT a cohort of 84 patients who were operable but chose LITT for treatment have shown a survival rate that is superior to most published series for surgical resection [60% survival at 5 years with LITT vs. 38% at 5 years for typical surgical series (47 below)]. This favorable increase in survival may be explained by the creation of HSPs and is supported by the findings of a well controlled study of implanted tumors in rat livers comparing tumor growth following surgical resection with tumor growth following LITT treatment (39).
Interstitial thermal therapies such as RFA, LITT, or microwave would achieve lesion access along the needle biopsy track. Extracorporeal approaches such as HIFU or Dowlatshahi reported on 54 cancers that were treated by laser therapy and followed by surgical resection to analyze the degree of necrosis.
Fornage et al. treated 21 breast cancers measuring no more than 20mm with RFA prior to resection and found upon excision that 20 were totally necrosed (41). Hayashi et al. (42) reported on 22 patients treated with RFA for tumors less than 3 cm in size. Following surgical resection complete coagulation necrosis was observed in 19 of 23 tumors. The procedure was well tolerated, cosmesis was excellent, and 95% of the patients would be willing to have the procedure again.
Image guidance for thermal ablation is critical in order to properly position the ablative device. The major challenge facing the implementation of thermal therapies relates to the need for intraoperative temperature feedback during the procedure in order to ascertain that the entire tumor has been subjected to temperatures that will insure cell death, obviating concerns about margin analysis. To date interstitial thermocouples have been used to provide feedback regarding the tumor temperature during the procedure but multiple sensors detract not only from the minimally invasive nature of the procedure but may well impede the consistent application of energy to the tumor. Several devices use thermistors which are attached to the RF tines or with a needle positioned near the laser fiber. While these methods provide temperature feedback at the location of the thermistor, they are unable to determine the temperature throughout the lesion during the ablation. 
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Thermal Mapping
A new method of thermal mapping has been described (43) that should aid all thermal ablative techniques. The technique requires an x-ray imaging system with a digital detector. The tumor being treated is placed in the x-ray field and a "mask" image is acquired before heat is applied to the tumor. As local tissue temperatures approach 42ºC the process of cell death begins. As the tissue temperature increases the time required to assure cell death decreases. At about 58ºC proteins begin to denature and at higher temperatures tissue coagulates. At 100ºC, a temperature which can occur at the tip of the ablative device, cell water vaporizes.
The denaturation and coagulation of tissue contained within approximately the same volume, produces density changes (44, 45) . As heat is transported from the central coagulation zone and conducted to surrounding tissues, an expanding coagulation zone develops and increases as a function of thermal power delivered over time (43 above). As the lesion is heated, periodic x-rays are taken and digitally subtracted from the mask. The successive subtracted images show the propagation of the change in density indicative of coagulation. Binning of pixels will increase the signal to noise ratio of the digital image, which helps to overcome overall system electronic, and quantum noise. Sophisticated software, which includes thermal conductivity modeling, allows measured density variations to form accurate thermal maps of tissue in and surrounding the ablation zone. The result is the creation of a thermal map which can be displayed to the physician. By visualizing the tumor temperature during the procedure the physician can avoid heating critical structures to lethal temperatures while insuring that the entire identified tumor is heated sufficiently to achieve cell necrosis. Figure 5 is an example of a thermal map created during an in vivo laser treatment of a porcine breeder sow's mammary gland.
While the technique has been demonstrated with planar xray views, it is apparent that improved visualization would result from implementing the mapping software with computer tomography (CT) systems. Additionally, new algorithms in development for cone beam CT applications hold promise to bring the technique to mobile c-arm systems in surgery as well as stereotactic breast biopsy systems.
MR imaging systems are able to provide physicians with several techniques that can monitor tumor temperature during a thermal ablation procedure. MR imaging has been used to guide LITT ablation of breast (46), head and neck, lymphatic, and liver tumors (47). A recent study using LITT to treat metastatic liver tumors demonstrated the significance of temperature mapping under MR guidance. Local tumor recurrence was reported at only 1.2-4.4% for liver metastases up to 5cm in over 603 patients with eight year follow up (48). These results depended on the ability of the radiologist to continue thermal treatment until the entire tumor reached killing temperature based on MR monitoring. While MR temperature mapping has demonstrated utility in mapping thermal ablation procedures, the availability, siting, and cost limit market adoption of MR mapping of thermal ablation procedures.
X-ray imaging thermal mapping offers an opportunity to treat all solid tumors with existing imaging systems. These systems include CT scanners, mobile c-arms, stereotactic breast biopsy systems, and interventional angio-digital systems. With appropriate guidance and thermal mapping capabilities, thermal ablative techniques could offer a minimally invasive and cost effective method of treating benign masses and small cancers. Given the growth in breast lesions requiring surgical intervention, ablative techniques may ultimately replace open surgery as a preferred treatment method for benign and small uni-focal invasive breast cancers.
